Show results for
Refine by
Clinical Feasibility Study Suppliers In Singapore
4 companies found
based inMelbourne, AUSTRALIA
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care. ...
MPC-25-IC is Mesoblast’s Phase 2 product candidate for the treatment of acute myocardial infarction. This is the first clinical study to evaluate an allogeneic cellular therapy delivered by intracoronary infusion in patients who have suffered ...
based inCambridge, MASSACHUSETTS (USA)
TriNetX is the global health research network that connects the world of drug discovery and development from pharmaceutical company to study site, and investigator to patient by sharing real-world data to make clinical and observational research ...
Ask the healthcare organizations who share their de-identified patient data to participate in your clinical study, right on our platform. Our live regional networks attribute each de-identified patient in your cohort back to their home healthcare ...
based inWaltham, MASSACHUSETTS (USA)
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are ...
Natural killer (NK) cells are innate lymphocytes that kill virally infected or malignant cells. Unlike T cells, NK cells function in an antigen independent manner, responding to anything they perceive as "non-self", including malignant cells. NK ...
based inBillerica, MASSACHUSETTS (USA)
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists ...